OBJECTIVE: To determine if apneic preterm infants currently treated with methylxanthines develop evidence of sleep deprivation from cumulative arousal and motor activational effects. STUDY DESIGN: Sleep, wake, arousal and actigraphic movements were monitored in extubated clinically stable premature infants (N=37). Neonates were free of other medications for >72 h and were grouped based on methylxanthine exposure: >5 days with caffeine (n=14), >5 days theophylline (n=13) or no prior exposure (n=10). RESULT: Duration of methylxanthine treatment predicted increased arousals, wakefulness and actigraphic movements, and decreased active sleep. Recording from 1200 to 0500 hours, methylxanthine-treated groups showed reductions in all arousal parameters: waking state, number of wake epochs, brief arousals and composite arousal index, and shorter fast-burst, sleep-related motility than untreated controls. CONCLUSION: In apneic preterms, chronic methylxanthine treatment appears to produce sleep deprivation secondary to the stimulatory action of methylxanthines on arousal and motor systems.
OBJECTIVE: To determine if apneic preterminfants currently treated with methylxanthines develop evidence of sleep deprivation from cumulative arousal and motor activational effects. STUDY DESIGN: Sleep, wake, arousal and actigraphic movements were monitored in extubated clinically stable premature infants (N=37). Neonates were free of other medications for >72 h and were grouped based on methylxanthine exposure: >5 days with caffeine (n=14), >5 days theophylline (n=13) or no prior exposure (n=10). RESULT: Duration of methylxanthine treatment predicted increased arousals, wakefulness and actigraphic movements, and decreased active sleep. Recording from 1200 to 0500 hours, methylxanthine-treated groups showed reductions in all arousal parameters: waking state, number of wake epochs, brief arousals and composite arousal index, and shorter fast-burst, sleep-related motility than untreated controls. CONCLUSION: In apneic preterms, chronic methylxanthine treatment appears to produce sleep deprivation secondary to the stimulatory action of methylxanthines on arousal and motor systems.
Authors: Carole L Marcus; Lisa J Meltzer; Robin S Roberts; Joel Traylor; Joanne Dix; Judy D'ilario; Elizabeth Asztalos; Gillian Opie; Lex W Doyle; Sarah N Biggs; Gillian M Nixon; Indra Narang; Rakesh Bhattacharjee; Margot Davey; Rosemary S C Horne; Maureen Cheshire; Jeremy Gibbons; Lorrie Costantini; Ruth Bradford; Barbara Schmidt Journal: Am J Respir Crit Care Med Date: 2014-10-01 Impact factor: 21.405
Authors: Gilbert Koch; Natalie Schönfeld; Kerstin Jost; Andrew Atkinson; Sven M Schulzke; Marc Pfister; Alexandre N Datta Journal: Pharmacol Res Perspect Date: 2020-06